SCHEMBL5545314

SCHEMBL5545314

NCCn1c(=O)c(C(=O)NCCCN2CCOCC2)c(O)c2ncc(Cc3ccc(F)cc3)cc21

nearest known ligand 0.47

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.47
CNR2 P34972 9/20 0.45
TSHR P16473 2/20 0.45
CNR1 P21554 6/20 0.44
PIK3CA P42336 1/20 0.44
HPGD P15428 2/20 0.43
LMNA P02545 2/20 0.43
NPSR1 Q6W5P4 2/20 0.43
KDM4E B2RXH2 2/20 0.42
GLA P06280 1/20 0.42
GAA P10253 1/20 0.42
MAPT P10636 1/20 0.42
RECQL P46063 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5545729 0.96 CNR2 (0.49) CNR2TSHRCNR1PIK3CAHPGD
SCHEMBL15163489 0.92 CNR2 (0.45) ALDH1A1CNR2TSHRCNR1PIK3CA
SCHEMBL5540707 0.92 CNR2 (0.47) ALDH1A1CNR2TSHRCNR1PIK3CA
Hydrochloric Acid SCHEMBL5545865 0.92 CNR2 (0.45) ALDH1A1CNR2TSHRCNR1PIK3CA
SCHEMBL15163633 0.91 CNR2 (0.46) ALDH1A1CNR2TSHRCNR1PIK3CA
Hydrochloric Acid SCHEMBL5546957 0.90 CNR2 (0.47) ALDH1A1CNR2TSHRCNR1PIK3CA
SCHEMBL5547037 0.90 KMT2A (0.45) ALDH1A1CNR2TSHRCNR1PIK3CA
SCHEMBL5545929 0.90 CNR2 (0.45) ALDH1A1CNR2TSHRCNR1PIK3CA
SCHEMBL15163675 0.90 CNR2 (0.46) ALDH1A1CNR2TSHRCNR1PIK3CA
SCHEMBL5547404 0.90 CNR2 (0.44) ALDH1A1CNR2TSHRCNR1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20150225399-A1 HIV INTEGRASE INHIBITORS VIIV HEALTHCARE CO (US) 2015-08-13 US disclosed
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS SHIONOGI & CO., LTD. (JP) 2014-09-11 US disclosed
EP-1720856-B1 HIV INTEGRASE INHIBITORS GLAXOSMITHKLINE LLC (US) 2013-08-14 EP disclosed
US-20070124152-A1 Hiv Integrase Inhibitors GLAXOSMITHKLINE LLC 2007-05-31 US disclosed
EP-1720856-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2006-11-15 EP disclosed
WO-2005077050-A2 HIV INTEGRASE INHIBITORS SMITHKLINE BEECHAM CORPORATION (US) 2005-08-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140256713-A1 2-OXONAPHTHYRIDINE-3-CARBOXAMIDES HIV INTEGRASE INHIBITORS BCDIN3D, DUT, SAMHD1 ALDH1A1 3812/4885CNR2 3954/4885TSHR 4052/4885
US-20150225399-A1 HIV INTEGRASE INHIBITORS ING2, API5, SAMHD1 ALDH1A1 3073/4885CNR2 4810/4885TSHR 4622/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.